Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
6 USD
5.63%
Market Closed
Updated:
May 16, 2024
Editas Medicine Inc
Total Current Liabilities
|
Editas Medicine Inc
Total Current Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Total Current Liabilities
$66.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$37.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.5B
|
CAGR 3-Years
24%
|
CAGR 5-Years
26%
|
CAGR 10-Years
24%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is Editas Medicine Inc's Total Current Liabilities?
Total Current Liabilities
66.5m
USD
66.5m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Total Current Liabilities amounts to 66.5m USD.
What is Editas Medicine Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
10%
10%
Over the last year, the Total Current Liabilities growth was 16%. The average annual Total Current Liabilities growth rates for Editas Medicine Inc have been 1% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
